{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:40:48Z","timestamp":1790617248548,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["www.bloodresearch.or.kr"],"crossmark-restriction":true},"short-container-title":["Blood Res"],"published-print":{"date-parts":[[2020,7,31]]},"DOI":"10.5045\/br.2020.s008","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T21:50:11Z","timestamp":1595886611000},"page":"S43-S53","update-policy":"https:\/\/doi.org\/10.5045\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Treatment of relapsed and refractory multiple myeloma"],"prefix":"10.1007","volume":"55","author":[{"given":"Ji Hyun","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405016"},{"key":"ref3","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328-46."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.356"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.508"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.04.014"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615187"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119473"},{"key":"ref10","unstructured":"Lenhoff S, Hjorth M, Turesson I, et al. Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica 2006;91:1228-33."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1414-5"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.10.009"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13067"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0280-8"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00507-x"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.273"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-193458"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.390"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707596"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112571"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.104"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-350009"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2555-0"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-358812"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5460"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4918"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.176"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.5032"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14549"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30354-1"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02704-z"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3728"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.05.017"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2616"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.970"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.147"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.3"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1893-z"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-517276"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-612069"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-682518"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.437"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-705210"},{"key":"ref55","unstructured":"Usmani SZ, Nahi H, Weiss BM, et al. Safety and efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed and refractory multiple myeloma: final results from GEN501 and SIRIUS. Blood (ASH Annual Meeting Abstracts) 2017;130(Suppl):3107."},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy177"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13712"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194282"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194118"},{"key":"ref60","unstructured":"San-Miguel J, Weisel K, Cook G, et al. Efficacy by cytogenetic risk status for daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone in relapsed or refractory multiple myeloma. Haematologica 2017;102:1-2."},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-360552"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Lonial S, Dimopoulos MA, Weisel K, et al. Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab+ lenalidomide\/dexamethasone (ELd) vs Ld in relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol (ASCO Annual Meeting Abstracts) 2018;36(Suppl):8040.","DOI":"10.1200\/JCO.2018.36.15_suppl.8040"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11228"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15679"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197704)39:4"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1952-5"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.055"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24954"},{"key":"ref69","unstructured":"Knop S, Straka C, Haen M, Schwedes R, Hebart H, Einsele H. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005;90:1287-8."},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.5045\/br.2016.51.3.193"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-395715"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.58"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70440-1"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.016"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28104"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30049-7"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.164"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111203"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2387"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2688"}],"container-title":["BLOOD RESEARCH"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pdf.medrang.co.kr\/BR\/2020\/055\/BR2055-00-08.pdf","content-type":"unspecified","content-version":"tdm","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T22:27:05Z","timestamp":1773354425000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.bloodresearch.or.kr\/journal\/view.html?doi=10.5045\/br.2020.S008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":81,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2020,7,31]]}},"alternative-id":["10.5045\/br.2020.S008"],"URL":"https:\/\/doi.org\/10.5045\/br.2020.s008","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]},"assertion":[{"value":"http:\/\/www.bloodresearch.or.kr\/journal\/view.html?doi=10.5045\/br.2020.S008","URL":"http:\/\/www.bloodresearch.or.kr\/journal\/view.html?doi=10.5045\/br.2020.S008","name":"the_journal","label":"Blood Res","group":{"name":"multiple_resolution","label":"Full text available at:"}},{"value":"2019-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}},{"value":"\u00a9 2020 The Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis","name":"copyright","label":"Copyright","group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article distributed unAcute myeloid leukemia, New FDA approvalsder the terms of the Creative Commons Attribution Non-Commercial License (http:\/\/creativecommons.org\/licenses\/by-nc\/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.","name":"license","label":"License","explanation":{"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},"group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}}]}}